UNASSIGNED: Glucagon-like polypeptide ( @entity8142 agonist treatment has multiple effects on @entity413 metabolism, supports the b cell, and promotes @entity353 . There are now five @entity6757 agonists in clinical use with more in development. @entity6757 treatment typically can induce a lowering of hemoglobin A1c (HbA1c) of 0.5-1.5% over time with @entity353 of 2-5%. In some individuals, a progressive loss of weight occurs. There is evidence that @entity6757 therapy opposes the loss of b cells which is a feature of type 2 @entity6 . The chief downside of @entity6757 treatment is the @entity344 disturbance which is one of the modes of action of the hormone; significant @entity390 , @entity391 , and @entity294 may lead to discontinuation of treatment. Although daily injection of @entity6757 agents is successful, the development of extended release preparations allows for injection once weekly, and perhaps much longer in the future. The indication for @entity6757 use is @entity6 , but now, liraglutide has been approved for primary treatment of @entity28 . When oral agents fail to control @entity413 levels in type 2 @entity6 , there is a choice between long-acting insulin and @entity6757 agonists as additional treatments. The lowering of @entity4051 c by either modality is equivalent in most studies. @entity1 lose weight with @entity6757 treatment and gain weight on insulin. There is a lower incidence of @entity4053 with @entity6757 therapy but a much higher incidence of @entity344 . Insulin dosing is flexible while @entity6757 agents have historically been administered at fixed dosages. Now, the use of combined long-acting insulin and @entity6757 agonists is promising a major therapeutic change. Combined therapy takes advantage of the benefits of both insulin and @entity6757 agents. Furthermore, direct admixture of both in the same syringe will permit flexible dosing, improvement of @entity413 levels, and reduction of both @entity4053 and gastrointestinal side effects.

Glucagon-like polypeptide agonists in XXXX : efficacy and tolerability, a balance.

@entity4051 :: ('3039', 'Gene') :: ['HbA1'] @entity1 :: ('9606', 'Species') :: ['Patients'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity353 :: ('MESH:D015431', 'Disease') :: ['weight loss'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes'] @entity28 :: ('MESH:D009765', 'Disease') :: ['obesity'] @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea'] @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting'] @entity344 :: ('MESH:D005767', 'Disease') :: ['gastrointestinal motility', 'gastrointestinal complaints'] @entity4053 :: ('MESH:D007003', 'Disease') :: ['hypoglycemia'] @entity6757 :: ('100125288', 'Gene') :: ['GLP-1'] @entity8142 :: ('2740', 'Gene') :: ['GLP-1) receptor'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']
@entity6 :: (MESH:D003920,Disease) :: ['type 2 diabetes mellitus']
